TYRA
Tyra Biosciences, Inc. Health Care Pharmaceutical Preparations Russell 3000
$21.07Close
$1.1BMarket cap
$14.28 – $39.6152-week range
Nov 4, 2026Next report
Highlights
Cautions
- Not in an uptrend 1 of 8 trend conditions
- Lagging the market RS 15 · weaker than 85% of stocks over 12 months
- Far from its high 47% below its 52-week high
- Distribution down-day volume 1.5× up-day volume over 50 sessions
- Results soon Nov 4, 2026, in 3 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
47%
1wk
up 3.0%
price change
1mo
down 3.7%
price change
12-month return
up 34%
market up 11% ·
its own up 27%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
4.4×
price / book
Earnings yield
down 12.6%
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 40%
return on equity
Free cash margin
—
-$95.3M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
5.4%
$1.13 a day · 2×ATR $18.80
RS
15 / 99
vs the universe
Trend
1 / 8
trend template
Relative volume
0.7×
vs 50-day average
Up/down volume
0.67
50 sessions
Implied move
—
no option chain · report Nov 4, 2026
Trend template · 1 of 8
- At least 30% above the 52-week low: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 5.8% over the year, from 51m to 54m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 4, 2026
Last shock
Aug 5, 2026-21% in one session3.0× volumeon results-18% since
Financials
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Operating income | -$9.3M | -$26.3M | -$58.9M | -$79.9M | -$104.2M | -$132.8M |
| Net income | -$9.3M | -$26.3M | -$55.3M | -$69.1M | -$86.5M | -$119.9M |
| Earnings per share | — | -$1.91 | -$1.32 | -$1.62 | -$1.51 | -$2.01 |
| Free cash flow | -$8.1M | -$24.4M | -$50.8M | -$50.9M | -$70.4M | -$95.3M |
| Cash | $15.2M | $302.2M | $251.2M | $58.0M | $92.0M | $77.4M |
| Shareholders' equity | -$13.6M | $301.7M | $257.8M | $204.3M | $343.2M | $259.2M |
| Shares outstanding | 1.83m | 41.44m | 42.35m | 43.02m | 50.75m | 53.71m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 4, 2026 | Quarterly ↗ | Jun 30, 2026 | 35d |
| May 13, 2026 | Quarterly ↗ | Mar 31, 2026 | 43d |
| Mar 2, 2026 | Annual ↗ | Dec 31, 2025 | 61d |
| Nov 5, 2025 | Quarterly ↗ | Sep 30, 2025 | 36d |
| Aug 14, 2025 | Quarterly ↗ | Jun 30, 2025 | 45d |
| May 8, 2025 | Quarterly ↗ | Mar 31, 2025 | 38d |
| Mar 27, 2025 | Annual ↗ | Dec 31, 2024 | 86d |
| Nov 7, 2024 | Quarterly ↗ | Sep 30, 2024 | 38d |
| Aug 7, 2024 | Quarterly ↗ | Jun 30, 2024 | 38d |
| May 9, 2024 | Quarterly ↗ | Mar 31, 2024 | 39d |
| Mar 19, 2024 | Annual ↗ | Dec 31, 2023 | 79d |
| Nov 7, 2023 | Quarterly ↗ | Sep 30, 2023 | 38d |
Current reports
| Filed | Disclosed |
|---|---|
| Sep 15, 2026 | Other events ↗ |
| Sep 9, 2026 | Other events ↗ |
| Aug 4, 2026 | Results ↗ |
| Jun 2, 2026 | Shareholder vote ↗ |
| May 13, 2026 | Results ↗ |
| Apr 17, 2026 | Director or officer change ↗ |
| Apr 2, 2026 | Director or officer change ↗ |
| Mar 4, 2026 | Other events ↗ |
| Mar 2, 2026 | Results ↗ |
| Dec 1, 2025 | Director or officer change ↗ |
| Nov 5, 2025 | Results ↗ |
| Aug 22, 2025 | Other events ↗ |